Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Past Presentations
-
EEV-Conjugated Oligonucleotide Results in Nuclear Foci Reduction and Aberrant Splicing Correction in DM1 Cell and Animal Models
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 13th International Myotonic Dystrophy Consortium Meeting (IDMC-13)
- On: June 23, 2022
DownloadJune 23, 2022 -
Endosomal Escape Vehicle (EEV) Platform for Enhanced Functional Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 4th Annual RNA Therapeutics Symposium: From Concept to Clinic
- On: June 22, 2022
DownloadJune 22, 2022 -
A Novel EEV-Conjugated PMO, ENTR-701, Reduces Nuclear Foci and Corrects Aberrant Splicing in Myotonic Dystrophy Type 1 Preclinical Models
- By: Amy Hicks, PhD, Principal Scientist, Entrada Therapeutics
- At: 2022 New Directions in Biology and Disease of Skeletal Muscle Conference
- On: June 20, 2022
DownloadJune 20, 2022 -
Development of ENTR-601-44, a Novel EEV-Conjugated PMO for Duchenne Muscular Dystrophy
- By: Nelsa Estrella, PhD, Principal Scientist, Entrada Therapeutics
- At: 2022 New Directions in Biology and Disease of Skeletal Muscle Conference
- On: June 20, 2022
DownloadJune 20, 2022 -
Development of Endosomal Escape Vehicles to Enhance the Intracellular Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 27th American Peptide Symposium
- On: June 13, 2022
DownloadJune 13, 2022 -
Exon Skipping and Read Through Agents Panel
- By: Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: CureDuchenne FUTURES 2022 Conference
- On: May 28, 2022
DownloadMay 28, 2022